Viridian Therapeutics Profit Margin

The latest profit margin for VRDN is -544.06% as of June 2026. That compares with -112806.89% in the prior-year period — up 99.5% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Viridian Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, VRDN's profit margin moved from -112806.89% to -544.06% — a 99.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Viridian Therapeutics's valuation or profitability profile.

Against Healthcare companies, VRDN currently prints -544.06% for profit margin, while the sector average sits near 13.89%. That is roughly 4016.9% below the sector mean. Large gaps often invite a closer look at Viridian Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Viridian Therapeutics converts resources into returns. At -544.06%, VRDN may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -112806.89% in the prior-year period — up 99.5% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting VRDN's profit margin (-544.06%), review year-over-year change from -112806.89%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.